**Notice of Intent to Certify Sole Source**

**To:** Interested Parties

**From: Ellen Swoger**

CIO, Applications

**Date:** 12/4/2023

**Re:** Sole Source Certification Number **SS9614** for Addition of an Assay to the Philips IntelliSpace Precision Medicine Platform

**Contact Email Address:** [solesource@umc.edu](mailto:solesource@umc.edu)

**Sole Source Certification Award Details**

Regarding UMMC Sole Source Certification Number 9614 for the Addition of an Assay to the Philips IntelliSpace Precision Medicine Platform, please be advised that UMMC intends to award the purchase of the Addition of an Assay to the oncology genomics workspace in the Philips IntelliSpace Precision Medicine Platform to Philips Healthcare, a division of Philips North America LLC as the sole source provider of the Philips IntelliSpace Precision Medicine Platform.

UMMC issues this notice in accordance with Mississippi state law, policy, and procedures for sole source procurements.

Sole Source Criteria

1. Where the compatibility of equipment, accessories, or replacement parts is the paramount consideration (and manufacturer is the sole supplier).
2. Where a sole supplier’s item is needed for trial use or testing.
3. Where a sole supplier’s item is to be required when no other item will service the needs of UMMC.

**Schedule**

|  |  |
| --- | --- |
| **Task** | **Date** |
| First Advertisement Date | December 8, 2023 |
| Second Advertisement Date | December 15, 2023 |
| Response Deadline from Objectors | December 26, 2023, at 3:00 p.m. Central Time |
| Notice of Award/No Award Posted | Not before December 26, 2023 |

**Project Details**

1. **Describe the commodity/service that the agency/institution is seeking to procure:**

The Philips IntelliSpace Precision Medicine (ISPM) Platform is a cloud-based precision medicine solution designed for care-providers and researchers to facilitate and optimize clinical decisions and operational excellence through standardized, efficient and evidence-based patient care. The Genomics Workspace module provides configurable automation of a pathologist or oncologist's workflow.UMMCoperates a genomic workflow that is triggered by a test order along with the processing of Next-Generation Sequencing (NGS) raw files. UMMC is planning to add a new assay: Archer™ FUSIONPlex™ Lung v2 panel (Archer Lung v2). The Archer Lung v2 is a 17 gene panel that is typically used to characterize patients with non-small cell lung-cancer.

1. **Explain why the commodity/service is the only one (1) that can meet the needs of the agency/institution:**

Philips holds the proprietary license and related authorizations for the Philips IntelliSpace Precision Medicine (ISPM) Platform; therefore, they are the sole provider of the addition of an assay to the genomics workspace in the platform.

1. **Explain why the source is the only person or entity that can provide the required commodity/service:**

No other vendor distributes or supports the Philips IntelliSpace Precision Medicine (ISPM) Platform. See supporting letter from Philips Healthcare, Attachment A.

1. **Explain why the amount to be expended for the commodity/service is reasonable:**

The estimated amount to be expended for the purchase of the addition of the assay Archer™ FUSIONPlex™ Lung v2 panel is $16,309.00. Please be advised that UMMC will determine if additional enhancements, upgrades, support, or equipment are within scope during the certification period and may increase the spending authority accordingly. Should Philips Healthcare change their name during this certification period, then UMMC will determine if a recertification is necessary.

This amount is within the expected price range for these products.

1. **Describe the efforts that the agency/institution went through to obtain the best possible price for the commodity/service:**

Pricing is compared against available market intelligence and identified discounts are pursued where applicable.

**Submission Instructions and Format of Response from Objecting Parties**

Interested parties who have reason to believe that addition of the assay Archer™ FUSIONPlex™ Lung v2 panel (hereafter, “Products”) should not be certified as a sole source should provide information in the Vendor Form for the State to use in determining whether or not to proceed with awarding the sole source to Philips Healthcare. The Vendor Form may be found at <http://www.dfa.state.ms.us/Purchasing/documents/ObjectiontoSoleSourceDetermination.pdf>.

Objections must include the certification in Attachment B.

Comments will be accepted at any time prior to Tuesday, December 26, 2023, at 3:00 p.m. (Central Time) to [solesource@umc.edu](mailto:solesource@umc.edu). Responses may be delivered via email to [solesource@umc.edu](mailto:solesource@umc.edu). UMMC WILL NOT BE RESPONSIBLE FOR DELAYS IN THE DELIVERY OF RESPONSES. It is solely the responsibility of the Interested Parties that responses reach UMMC on time. Responses received after the deadline and responses that lack all required information will be rejected. UMMC reserves the right to inspect Interested Party’s commodity for comparison purposes.

If you have any questions concerning the information above or if we can be of further assistance, please contact [solesource@umc.edu](mailto:solesource@umc.edu).

Attachment A: Vendor Correspondence

Attachment B: Objection Certification

Attachment B

**SUBMITTED IN RESPONSE TO**

**Sole Source Certification No. SS9614**

**Accepted until Tuesday, December 26, 2023, at 3:00 p.m.**

I certify that the information contained in this objection is true and accurate to the best of my knowledge. I understand that UMMC will investigate all statements made in this objection and that any false or misleading information provided may result in adverse action.

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

Objector Name

Objector’s title

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

Date